Covid-19: Global Campaign to Vaccinate Most Likely Stalled Despite More Approvals - The New York Times (nytimes.com)

Azt írják, a kínaiak sem feltétlenül fogják tartani amit ígértek, érdekes lesz.

Vaccine access could improve even more next week when the W.H.O. considers another Chinese shot, made by Sinovac. But the fanfare may be short-lived. While China has claimed it can make up to 5 billion doses by the end of this year, Chinese officials say the country is struggling to manufacture enough doses for its own population and are cautioning a pandemic-weary world to keep expectations in check.

“This should be the golden time for China to practice its vaccine diplomacy. The problem is, at the same time, China itself is facing a shortage,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations. “So in terms of global access to vaccines, I don’t expect the situation to significantly improve in the coming two to three months.”

Na de jöhet a Curevac.

Vaccine experts are particularly curious to see late-stage clinical trial results of a small German company called CureVac, expected as early as next week. The vaccine is made with the same RNA method as Moderna and Pfizer-BioNTech, but it has an important advantage. While those two vaccines have to be kept in a deep freezer, CureVac’s vaccine stays stable in a refrigerator — meaning it could more easily deliver the newly discovered power of RNA vaccines to hard-hit parts of the world.

"Felesleges szigetelni a nyílászárókat, ha az ereszcsatornán szökik a meleg."